Our Community
Latest Photos
Latest Videos
Our Blog
Forum
Latest Events
CLOSE

About James Cullem

James Cullem /Basic Information

  • Gender

  • Birthdate

    08-01
  • About James Cullem

    James Cullem is the chief executive officer and co-founder of Paradigm Oncology, Inc., with more than two decades of experience guiding early-stage life science businesses in their start-up, management, and progress. Cullem’s past pedigree includes associations with intellectual property (I.P.) management, law, and technology firms Aurora Nova, LLC, McCarter & English, LLP, Enzymatics, Inc. and Cell Signaling Technology, Inc. James Cullem has also served as a bench researcher at J. David Gladstone Institute of Immunology & Virology and Chiron Corporation (now Novartis Diagnostics).

    James Cullem is also the former chief executive officer and co-founder of Halcyon Diagnostics, Inc., a startup firm dedicated to the development of tumor-profiling diagnostics to guide personalized medicine for late-stage cancer patients. Cullem is a proud member of the 1999 graduating class (Juris Doctorate) at the highly-ranked I.P. program of Franklin Pierce Law Center (Concord, N.H.), now incorporated with the University of New Hampshire law school.

    Following graduation from the University of California – Davis (1990, B.S. Biochemistry), James Cullem expanded his biotechnology skills and knowledge base by serving as a bench Research Associate for both a leading California biotechnology company and a leading academic research center. Subsequently, he completed graduate coursework in Toxicology at the Colorado State University, Ft. Collins.

    After receiving his Juris Doctorate degree, Cullem joined Mintz, Levin, a top Boston law firm, serving as a Patent Attorney in its life sciences and intellectual property group. Over the years, James Cullem has leveraged his experience to benefit a number of international clients seeking assistance with discovery technologies, drug targets, genomics, molecular diagnostics, diagnostic biomarkers, reagents, and proteomics. After losing his mother-in-law to glioblastoma (malignant brain cancer), James Cullem dedicated himself to improving patient care and treatment options for the disease.

    A published author and guest speaker, James Cullem is recognized for his leadership and business acumen about issues related to intellectual property management, particularly in early-stage company settings. His work has been showcased in the top journal Nature Biotechnology, among other national industry publications.

  • Languages Spoken

James Cullem /Contact Information

James Cullem /Education

Connections

    No Connections yet
James Cullem
  • James Cullem Member since
    Tuesday, 28 January 2014 08:49
  • James Cullem Last online
    Never logged in
  • James Cullem Profile views
    1,413 views

About James Cullem

James Cullem /Basic Information

  • Gender

  • Birthdate

    08-01
  • About James Cullem

    James Cullem is the chief executive officer and co-founder of Paradigm Oncology, Inc., with more than two decades of experience guiding early-stage life science businesses in their start-up, management, and progress. Cullem’s past pedigree includes associations with intellectual property (I.P.) management, law, and technology firms Aurora Nova, LLC, McCarter & English, LLP, Enzymatics, Inc. and Cell Signaling Technology, Inc. James Cullem has also served as a bench researcher at J. David Gladstone Institute of Immunology & Virology and Chiron Corporation (now Novartis Diagnostics).

    James Cullem is also the former chief executive officer and co-founder of Halcyon Diagnostics, Inc., a startup firm dedicated to the development of tumor-profiling diagnostics to guide personalized medicine for late-stage cancer patients. Cullem is a proud member of the 1999 graduating class (Juris Doctorate) at the highly-ranked I.P. program of Franklin Pierce Law Center (Concord, N.H.), now incorporated with the University of New Hampshire law school.

    Following graduation from the University of California – Davis (1990, B.S. Biochemistry), James Cullem expanded his biotechnology skills and knowledge base by serving as a bench Research Associate for both a leading California biotechnology company and a leading academic research center. Subsequently, he completed graduate coursework in Toxicology at the Colorado State University, Ft. Collins.

    After receiving his Juris Doctorate degree, Cullem joined Mintz, Levin, a top Boston law firm, serving as a Patent Attorney in its life sciences and intellectual property group. Over the years, James Cullem has leveraged his experience to benefit a number of international clients seeking assistance with discovery technologies, drug targets, genomics, molecular diagnostics, diagnostic biomarkers, reagents, and proteomics. After losing his mother-in-law to glioblastoma (malignant brain cancer), James Cullem dedicated himself to improving patient care and treatment options for the disease.

    A published author and guest speaker, James Cullem is recognized for his leadership and business acumen about issues related to intellectual property management, particularly in early-stage company settings. His work has been showcased in the top journal Nature Biotechnology, among other national industry publications.

  • Languages Spoken

James Cullem /Contact Information

James Cullem /Education

Connections

    No Connections yet